简介：
Overview
This study addresses the challenge of drug-induced liver injury (DILI) in drug development by introducing a protocol utilizing a liver microphysiological system (MPS). The MPS effectively maintains functional liver microtissues for up to four weeks to predict the DILI liability of novel compounds.
Key Study Components
Research Area
- Drug-induced liver injury (DILI)
- Microphysiological systems (MPS)
- Preclinical safety testing
Background
- Drug-induced liver injury is a leading cause of drug failure.
- A reliable in vitro model is needed for assessing drug safety.
- Existing culture systems are less predictive than the proposed MPS.
Methods Used
- The protocol involves coculturing primary hepatic cells in the MPS.
- The system maintains liver microtissues that replicate human physiology.
- Enzymatic assays and viability assessments are conducted for quality control.
Main Results
- High functionality of liver microtissues was confirmed through multiple metrics.
- Positive assessment of cellular responses to drug dosing.
- Demonstrated reproducibility and predictive ability of the MPS.
Conclusions
- This study provides a robust method for predicting DILI in drug candidates.
- It highlights the importance of advanced in vitro models in safety testing.
What is drug-induced liver injury?
Drug-induced liver injury is damage to the liver caused by medications, which can lead to drug failure during development.
How does the MPS function?
The MPS maintains functional liver microtissues for assessing the effects of drugs in a human-relevant context.
What are some key assays used in this research?
Lactate dehydrogenase and urea assays are utilized to assess liver functionality and cell viability.
How long can liver microtissues be maintained?
The liver microtissues can be cultured for up to four weeks under the MPS.
What advantages does MPS provide over traditional cultures?
The MPS model is more predictive of human responses compared to simpler 2D or even complex 3D cultures.
Why is this research important?
It provides a new avenue for preclinical safety assessments to improve drug development efficiency.
Which factors contribute to DILI?
Various factors including the drug's chemical properties and patient-specific metabolic responses can contribute to DILI.
繁體中文
